Table 4 Adverse events reported among participants enrolled in 2017–2018 therapeutic efficacy study, Burkina Faso
Niangoloko | Nanoro | Gourcy | ||||
|---|---|---|---|---|---|---|
AL (n = 116) | DP (n = 118) | AL (n = 117) | DP (n = 114) | AL (n = 120) | DP (n = 118) | |
Itchiness | 0 | 0 | 0 | 0 | 1 | 0 |
Otitis media | 1 | 0 | 0 | 0 | 0 | 0 |
Cough | 14 | 14 | 4 | 1 | 3 | 2 |
Abdominal pain | 2 | 7 | 2 | 5 | 0 | 1 |
Skin rash | 0 | 2 | 2 | 0 | 0 | 1 |
Oral thrush | 0 | 0 | 0 | 0 | 0 | 0 |
Furunculosis | 0 | 1 | 0 | 0 | 0 | 0 |
Vomiting | 12 | 23 | 15 | 18 | 6 | 13 |
Death | 0 | 0 | 0 | 0 | 1 | 0 |